VinSan Therapeutics

VinSan Therapeutics is a pre-clinical stage biotechnology company focused on developing transformative small molecule therapies for Alzheimer's disease and other neurodegenerative disorders. The company's research centers on the Amyloid Precursor Protein Intracellular Domain (AICD) signaling pathway, which plays a critical role in the pathogenesis of Alzheimer's by modulating gene expression and promoting neurotoxicity. By utilizing proprietary small molecule inhibitors to target this specific pathway, VinSan aims to address the underlying mechanisms of neurodegeneration rather than focusing solely on amyloid plaque clearance. Founded as a spin-off from the Cleveland Clinic, the company is advancing its lead candidates through IND-enabling studies to provide a novel disease-modifying approach for patients.